T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| 1 |
Humana
HUM
|
+$2.39B |
| 2 |
UnitedHealth
UNH
|
+$1.47B |
| 3 |
GE Aerospace
GE
|
+$1.33B |
| 4 |
Amazon
AMZN
|
+$1.18B |
| 5 |
AbbVie
ABBV
|
+$1.13B |
Top Sells
| 1 |
Boeing
BA
|
+$1.56B |
| 2 |
Nike
NKE
|
+$1.42B |
| 3 |
Becton Dickinson
BDX
|
+$1.33B |
| 4 |
Alibaba
BABA
|
+$1.23B |
| 5 |
JPMorgan Chase
JPM
|
+$1.22B |
Sector Composition
| 1 | Technology | 22.97% |
| 2 | Healthcare | 18.52% |
| 3 | Consumer Discretionary | 13.27% |
| 4 | Financials | 12.08% |
| 5 | Communication Services | 10.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
226
Equitable Holdings
EQH
$15.9B
| $609M | 0.1% |
42,148,705
+2,124,765
| +5% | +$30.7M |
|
|
GLIBA
227
DELISTED
GCI Liberty, Inc. Class A Common Stock (DE)
GLIBA
| $601M | 0.1% |
10,554,183
+129,592
| +1% | +$7.38M |
|
228
Eli Lilly
LLY
$662B
| $595M | 0.09% |
4,292,595
+109,970
| +3% | +$15.3M |
|
229
Assurant
AIZ
$10.7B
| $595M | 0.09% |
5,719,425
-31,515
| -0.5% | -$3.28M |
|
230
Xcel Energy
XEL
$42.4B
| $593M | 0.09% |
9,838,082
-6,261,925
| -39% | -$378M |
|
231
EOG Resources
EOG
$64.2B
| $577M | 0.09% |
16,052,779
+2,234,925
| +16% | +$80.3M |
|
232
Cintas
CTAS
$81.7B
| $573M | 0.09% |
13,227,688
+8,501,168
| +180% | +$368M |
|
233
Idexx Laboratories
IDXX
$52.2B
| $572M | 0.09% |
2,362,254
-1,275,881
| -35% | -$309M |
|
234
News Corp Class A
NWSA
$16.9B
| $569M | 0.09% |
63,411,876
+3,474,993
| +6% | +$31.2M |
|
235
Neurocrine Biosciences
NBIX
$14.3B
| $569M | 0.09% |
6,570,771
-720,526
| -10% | -$62.4M |
|
|
WUBA
236
DELISTED
58.COM INC
WUBA
| $568M | 0.09% |
11,660,482
+1,783,325
| +18% | +$86.9M |
|
237
Charter Communications
CHTR
$36B
| $563M | 0.09% |
1,290,857
+233,049
| +22% | +$102M |
|
238
AstraZeneca
AZN
$253B
| $562M | 0.09% |
12,581,512
+556,539
| +5% | +$24.9M |
|
|
COUP
239
DELISTED
Coupa Software Incorporated
COUP
| $559M | 0.09% |
3,999,478
-55,104
| -1% | -$7.7M |
|
240
Wabtec
WAB
$32.6B
| $558M | 0.09% |
11,600,649
-2,996,546
| -21% | -$144M |
|
241
ConocoPhillips
COP
$114B
| $556M | 0.09% |
18,042,569
+6,802,761
| +61% | +$210M |
|
242
Boston Scientific
BSX
$160B
| $553M | 0.09% |
16,942,211
+835,933
| +5% | +$27.3M |
|
243
Toro Company
TTC
$7.96B
| $551M | 0.09% |
8,469,339
-174,697
| -2% | -$11.4M |
|
244
Bristol-Myers Squibb
BMY
$95.1B
| $540M | 0.09% |
9,694,840
-1,468,911
| -13% | -$81.9M |
|
245
ICU Medical
ICUI
$3.22B
| $540M | 0.09% |
2,674,231
+89,469
| +3% | +$18.1M |
|
246
Costco
COST
$431B
| $534M | 0.08% |
1,871,770
+85,455
| +5% | +$24.4M |
|
247
MarketAxess Holdings
MKTX
$6.99B
| $533M | 0.08% |
1,602,390
-180,662
| -10% | -$60.1M |
|
248
Credicorp
BAP
$20.9B
| $533M | 0.08% |
3,724,730
+543,335
| +17% | +$77.7M |
|
249
Atmos Energy
ATO
$26.3B
| $517M | 0.08% |
5,210,553
-212,076
| -4% | -$21M |
|
250
Franco-Nevada
FNV
$38B
| $513M | 0.08% |
5,192,600
-701,336
| -12% | -$69.3M |
|